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ABSTRACT
Repinotan HCl (repinotan, BAY x 3702), a highly selective 5-HT1A receptor agonist
with a good record of safety was found to have pronounced neuroprotective effects in ex-
perimental models that mimic various aspects of brain injury. Repinotan caused strong,
dose-dependent infarct reductions in permanent middle cerebral artery occlusion, transient
middle cerebral artery occlusion, and traumatic brain injury paradigms. The specific
5-HT1A receptor antagonist WAY 100635 blocked these effects, indicating that the neuro-
protective properties of repinotan are mediated through the 5-HT1A receptor.
The proposed neuroprotective mechanisms of repinotan are thought to be the result of
neuronal hyperpolarization via the activation of G protein-coupled inwardly rectifying K+
channels upon binding to both pre- and post-synaptic 5-HT1A receptors. Hyperpolarization
results in inhibition of neuron firing and reduction of glutamate release. These mecha-
nisms, leading to protection of neurons against overexcitation, could explain the neuropro-
tective efficacy of repinotan per se, but not necessarily the efficacy by delayed adminis-
tration. The therapeutic time window of repinotan appeared to be at least 5 h in in vivo
animal models, but may be even longer at higher doses of the drug.
Experimental studies indicate that repinotan affects various mechanisms involved in
the pathogenesis of brain injury. In addition to the direct effect of repinotan on neuronal
hyperpolarization and suppression of glutamate release this compound affects the death-
inhibiting protein Bcl-2, serotonergic glial growth factor S-100â and Nerve Growth
Factor. It also suppresses the activity of caspase-3 through MAPK and PKCá; this effect
may contribute to its neuroprotective efficacy. The dose- and time-dependent neuropro-
tective efficacy of repinotan indicates that the drug is a promising candidate for prevention
379
CNS Drug Reviews
Vol. 11, No. 4, pp. 379–402
© 2005 Neva Press, Branford, Connecticut
Address correspondence and reprint requests to: Dr. Paul G. M. Luiten, P.O. Box 149750, AA Haren, The
Netherlands; E-mail: p.g.m.luiten@rug.nl.
of secondary brain damage in brain-injured patients suffering from acute ischemic stroke.
Unfortunately, however, the first, randomized, double blind, placebo-controlled clinical
trial did not demonstrate the efficacy of repinotan in acute ischemic stroke.
INTRODUCTION
Stroke
At the end of the 20th century stroke was the third leading cause of death and was
responsible for approximately 5.5 million deaths in the Western World, accounting for
approximately 10% of all deaths. From 2002 on, however, it became the second most
common cause of death in the world. While 90% of all acute stroke deaths are in people
over 65 years of age, traumatic brain injury (TBI) caused by accidents is the most
common cause of mortality and morbidity in adults under 40 years of age. Although the
survival rates for acute stroke and TBI are improving, they are still low. Acute stroke is
not lethal in the majority of patients with only 8–20% of patients dying within the first 30
days. However, permanent neurological deficits remain in 50% of patients and more than
25% require long-term care. Both conditions, stroke and TBI, are associated with an insuf-
ficient blood supply in affected brain regions that may lead to motor, cognitive and other
behavioral impairments dependent on the location and size of the affected brain area.
These outcomes represent a substantial social and economic burden. In 1993, the total cost
of stroke for society was estimated to be $18 billion in the USA alone (65,66,122).
Ischemic Cell Death and Different Strategies for Neuroprotection
After the onset of ischemia, loss of energy stores leads to ionic imbalance and the
breakdown of the energy-driven membrane potential. This induces neurotransmitter re-
lease into the extracellular space and inhibition of their uptake, in particular the uptake of
the major mammalian excitatory transmitter glutamate (12,120,132). Subsequently, con-
tinuous activation of glutamate receptors [i.e., ionotropic NMDA (N-methyl-D-aspartate),
AMPA (á-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid), kainate and metabotro-
pic glutamate receptors] will promote excessive postsynaptic Ca2+ influx and indirect
mobilization of intracellular calcium stores.
This non-physiological rise in intracellular Ca2+, together with the repeated membrane
depolarization or even general loss of membrane potential, constitutes a positive feedback
loop that triggers an array of downstream intracellular processes that ultimately lead to the
degradation of membranes and proteins that are essential for cellular integrity. The two
most fundamental downstream mechanisms lead either to a rapid cell necrosis or to a
relatively delayed apoptotic-like cell death (83,86). As a result, the neuronal dysfunction
andor death represent new sources of neurotoxic glutamate (133). Thus, at least three
fundamental mechanisms can be distinguished in the process of ischemic cell death: exci-
totoxicity and ionic imbalance, oxidativenitrosative stress, and apoptotic-like cell death.
These mechanisms mediate injuries within neurons, glia, and vascular elements, and at the
subcellular level they affect the functional characteristics of mitochondria, nuclei, cell
membranes, endoplasmic reticulum, and lyzosomes (83,86,94).
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Since cell death after ischemia is associated with an overstimulation of the neurons, re-
search has focused on inhibiting neuronal activity immediately after injury and conse-
quently preventing cell death after ischemia. Because of the prominent role of glutamate
in excitotoxicity, neuroprotective therapy focused first on glutamate and on glutamate re-
ceptors like the NMDA receptor, which contributes prominently to Ca2+ influx (27), and
also on AMPA receptors (18). Competitive and non-competitive NMDA antagonists have
been reported to attenuate histopathology, and in certain instances to alleviate functional
outcome (79,108,113,114,130). However, despite their effectiveness in experimental
models of traumatic or ischemic brain injury, clinical trials with NMDA receptor antago-
nists revealed concerns about their safety, efficacy and tolerance. Glutamate antagonists,
directly acting at the postsynaptic glutamate receptors, have considerable side effects.
They produced hypotension and psychotomimetic effects in humans, and neurotoxic
injury in animals (72,109,146). Two possible factors contributing to the unsuccessful
clinical outcomes are differences in pathogenic mechanisms and therapeutic windows be-
tween clinical and experimental conditions (38). Glutamate antagonists have been shown
to lack clinical efficacy and specificity in human trials and their further development has
been curtailed (30,40,78).
Consequently, alternative strategies have been explored to alleviate neuronal cell death
after cerebral ischemia. These approaches, all of which were designed to counteract the
consequences of excessive ischemia-induced neuronal depolarization, include antagonists
of voltage-sensitive calcium and sodium channels (14,67,90,110,124,135), glutamate
synthesis inhibitors, glutamate release antagonists and inhibitors of second messenger
cascades and downstream regulatory pathways involved in glutamatergic signaling (112).
It became obvious that the search for new neuroprotective strategies would include stimu-
lation of neuronal processes capable of preventing membrane depolarization by inducing
hyperpolarization. Within this framework the serotonin (5-HT) and in particular the
5-HT1A receptor subtypes came into focus because of their hyperpolarizing efficacy, and
their widespread distribution in forebrain areas which are prone to ischemic injury
(33,115).
5-HT1A Receptor Agonists in Neuroprotection
Initially, the role of the serotonergic system in the pathophysiology of cerebral ische-
mia was not understood, but considerable progress has been made in recent years. The
concentration of 5-HT in the cerebral cortex was found to be decreased in the ischemic
brain (74). However, neurotoxin that destroys 5-HT system (5,7-dihydroxytryptamine),
increases neuronal death after ischemia in gerbil hippocampus (105). In addition, rapid en-
hancement of serotonergic sprouting was demonstrated in response to excitotoxic stimuli
in different brain areas (54,148) suggesting a probable enhanced signaling.
5-HT1A receptor is one of several subtypes through which serotonin exerts its neuronal
effects (63). It is widely distributed within the brain, both pre- and postsynaptically. Some
5-HT1A receptors are called autoreceptors, they are located on the cell soma and dendrites
of 5-HT neurons (139). Others are highly expressed postsynaptically in areas of the brain
that are most sensitive to neuronal damage following ischemic stroke or brain trauma,
such as hippocampus (CA1 and CA3 sectors and dentate gyrus), cerebral cortex and basal
forebrain nuclei (24,31,106). The 5-HT1A receptors exert an inhibitory effect on the firing
activity of neurons in these brain areas.
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Stimulation of postsynaptic 5-HT1A receptors is known to cause neuronal hyperpolari-
zation, most likely by activating G protein-coupled inwardly rectifying K+ channels (16,
33,68). Consequently, neuronal activity is suppressed due to increased resistance of the
neuronal membrane to glutamate-induced depolarization and overstimulation (i.e., excito-
toxicity) (7). In addition, 5-HT1A receptor agonists produce voltage-independent blockade
of N-, P-Q-, and T-type voltage-dependent Ca2+ channels via G-protein-mediated sig-
naling mechanisms or via a membrane-delimited pathway, respectively (137). Further-
more, 5-HT1A signaling inhibits L-type voltage-dependent Ca
2+ channel through a G-pro-
tein-mediated diffusible cytosolic messenger (19), and by this way abrogate Ca2+ entry
into nerve cells (121).
It has also been reported that 5-HT1A receptor agonists can reduce glutamate release
from nerve terminals (121,134), which is most likely mediated through activation of pre-
synaptic 5-HT1A receptors located on glutamatergic terminals (95,116).
Recently 5-HT1A receptor agonism was shown to inhibit apoptotic cell death in cul-
tured neurons from chick embryo (5) as well as in neuronal HN-2-5 cells (1). There is
strong evidence to support the role of programmed cell death in cerebral ischemia (82,91),
which points to the importance of increasing the time window for therapeutical interven-
tion (81).
Based on the above considerations, it appears that selective agonists of the 5-HT1A re-
ceptor may offer a new approach to neuroprotection in neurodegenerative disorders such
as stroke, traumatic brain injury (33) and probably also Alzheimer’s disease (84). Several
5-HT1A agonists, such as buspirone, urapidil, ipsapirone, gepirone, and 8-OH-DPAT have
been shown to have neuroprotective properties in different models of cells damage in vitro
and in vivo (15,95,115,131). However, all compounds investigated so far had limited
5-HT1A receptor selectivity, affinity andor intrinsic activity. The limited selectivity may
be partly explained by brain region-dependent differences in receptor reserve or in the
nature of receptor-effector coupling (31). It was suggested that the therapeutic spectrum of
a 5-HT1A receptor ligand could be optimized by increasing the level of intrinsic activity, at
different pre- and postsynaptic 5-HT1A receptors populations (31,32). These findings and
considerations stimulated the search for a more selective 5-HT1A-receptor agonist that
might exert neuroprotection also by inhibiting neuronal activity.
REPINOTAN
Pharmacokinetics
Recently, a methylchroman derivative, repinotan HCl (will be referred to as repinotan
in this manuscript) also known as BAY x 3702; or R-(–)-2-{4-[(chroman-2-ylmethyl)-
amino]-butyl}-1,1-dioxo-benzo[d]isothiazolone hydrochloride (Fig. 1) has been synthe-
sized at Bayer AG Healthcare, Wuppertal, Germany, and characterized in biochemical,
electrophysiological and behavioral assays as a novel, highly potent, highly selective and
orally active 5-HT1A receptor full agonist (33,35,37).
Most importantly, repinotan was found to have pronounced long-lasting neuroprotect-
ive effects in animal models of focal cerebral ischemia (permanent middle cerebral artery
occlusion, p-MCA-O), of reperfusion injury (transient middle cerebral artery occlusion,
t-MCA-O), and of traumatic brain injury (TBI) (33,61,62).
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The compound is highly soluble in water (2.1 g100 mL) (34). The half-life of repino-
tan HCl in plasma is relatively short (t12 = 0.6 h in rat; 0.4 h in rhesus monkeys; 1.2 h in
human), and the drug is extensively metabolized. Only 0.5% of the administered drug is
found unchanged in plasma or urine of rats (33).
Rapid penetration of the brain tissue is thought to be essential for the neuroprotective
efficacy of drugs. However, the distribution of drugs in the ischemic brain is likely to be
different than in the normal brain (87). Following cerebral ischemia, biphasic openings of
blood-brain barrier (BBB) are common and the severity and duration of the ischemic
insult affects the spatial and temporal pattern of drug distribution in the brain (76).
[14C]Repinotan passes the intact BBB of healthy rats rapidly and extensively (126,
127). Repinotan passes BBB in unchanged form; its distribution equilibrium of the free
drug in blood and brain is reached immediately after the start of infusion. The concentra-
tions of the drug in blood and brain are identical, indicating that the drug crosses BBB
freely in both directions with diffusion as a driving force. However, the penetration of
repinotan into ischemic brain areas is dependent on time of drug administration in relation
to injury. The distribution pattern of [14C]repinotan, administered either at 13 min or at 5 h
after pMCA-O to rats was identical with that in healthy controls. However, when adminis-
tered at 18 h after pMCA-O the drug was not able to pass BBB (127).
Toxicology
By single i.v. injection, repinotan was well tolerated by dogs and rabbits. It had low to
moderate toxicity in rodents (LD50 = 13 and 27 mgkg i.v. in rats and mice, respectively).
By repeated administration to rats, dogs or primates, repinotan produced predominantly
behavioral changes, suggesting that the central nervous system (CNS) is the primary target
organ. The threshold plasma concentration for the CNS side effects of repinotan was
50 ìgL (33,92). Repinotan did not seem to have any effect on male fertility and early em-
bryonic development, when administered to rats before and during the mating period. At
doses up to 0.1 mgkg repinotan had no effects on estrous cycle in rats. Signs of embryo-
toxicity were observed, but only at maternally toxic doses. Experiments on genotoxicity in
seven different test systems revealed neither mutagenic nor clastogenic properties of repi-
notan. Repinotan was also inactive with respect to DNA repairdamage induction (33,92).
Studies with repinotan in healthy human subjects demonstrated favorable safety and
tolerability profiles. The drug had no clinically significant effects on blood pressure, heart
rate, ECG, or clinical chemistry (33,107). Some subjects demonstrated a prolonged elimi-
nation of repinotan. These subjects had reduced cytochrome P450 II D6 activity (33).
Cytochrome P450 II D6 is encoded by a polymorphic gene, and reduced expression of this
cytochrome occurs in only 1% of the Asian population, whereas in Caucasians, African
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Fig. 1. Molecular structure of BAY x 3702 (Repinotan HCl).
Americans and Hispanics it is 5 to 8% (33). However, prolonged elimination of repinotan
was not associated with adverse events in these subjects.
The safety and tolerability of three different doses (0.5, 1.25, or 2.50 mgday) of repi-
notan was assessed in patients with severe traumatic brain injury (107). By continuous
infusion for 7 days repinotan had no apparent adverse effects on intracranial pressure, he-
modynamics or clinical chemistry. As expected, repinotan did not increase the risk of sei-
zures, or the incidence and severity of adverse events. No further safety concerns were
raised during the 3 months period after treatment.
Neuroprotectective Properties
Neuroprotective properties of repinotan in brain damage after ischemia have been
studied in vitro and in vivo. It has been shown that repinotan activates 5-HT1A receptors ef-
fectively in several pathways, which are involved in either neuroprotection or recovery of
neuronal function.
In vitro
In pre- and post-injury incubation protocols repinotan prevented neuronal damage.
Exposure to repinotan protected rat cortical and hippocampal neurons in cultures from
apoptosis induced by 25 nM staurosporine (136). Also in mixed rat hippocampal neuro-
nalglial cultures subjected to 24-h serum deprivation (4) or exposure to glutamate tox-
icity repinotan was neuroprotective (129). After staurosporine-induced apoptosis, re-
pinotan, at 50 pM to 1 ìM, reduced the release of lactate dehydrogenase, DNA fragmen-
tation, and apoptotic body formation in a concentration-dependent manner (136). This
indicated a selective and specific mode of action in accordance with its reported high
potency and selectivity (33). However, at 5 pM repinotan did not prevent cell death. Also,
if staurosporine concentrations were higher than 100 nM repinotan was ineffective The
latter may be due to the fact that with increasing concentrations of staurosporine multiple
pathways leading to apoptotic cell death are activated, which are not affected by repinotan
(136).
In vivo
Various accepted models that mimic different aspects of human brain injury were used
to examine the neuroprotective properties of repinotan:
1) permanent focal cerebral ischemia model involving occlusion of the middle cerebral
artery (pMCA-O) (102),
2) reperfusion injury model by transient middle artery occlusion (tMCA-O) (118), and
3) traumatic brain injury (TBI) model involving induction of acute subdural hematoma
(aSDH) (58).
The therapeutic window for repinotan has been also studied. This is extremely im-
portant because under clinical conditions there is usually a considerable delay between the
onset of stroke, hospitalization, diagnosis, and the first pharmacological intervention (97).
Two different administration techniques have been used in the evaluation of neuroprotec-
tive properties of repinotan. The compound was administered either by triple bolus in-
jection or by continuous infusion over a 4 h period.
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Permanent middle cerebral artery occlusion (pMCA-O)
By triple bolus injection (at 0, 2, and 4 h after pMCA-O), repinotan, at 1 to 10 ìgkg
had pronounced neuroprotective effect. The maximal infarct volume reduction was 73% at
3 ìgkg of the drug as assessed in rats at 7 days treatment (62,97). At lower or higher
doses repinotan had less neuroprotective efficacy (97).
Repinotan produced a strong and dose-dependent reduction in infarct size when admin-
istered by continuous infusion over a 4 h period, starting immediately after occlusion. A
reduction was observed at the drug doses of 0.3, 1, 3, 10, and 30 ìgkgh. Again, a de-
crease in the efficacy was observed at lower and higher doses of repinotan (U-shape
curve) (97). Strongest infarct volume reduction was found within the 1–10 ìgkgh dose
range, with 59–65% infarct reduction (62,97). Other investigators also found similar mag-
nitude of protection after infusion of repinotan at 3 or 10 ìgkgh for 4 h (57 and 55%, re-
spectively), starting immediately after occlusion in the pMCA-O model (129).
Transient middle cerebral artery occlusion (tMCA-O)
In rats subjected to tMCA-O repinotan (1, 10, or 100 ìgkgh i.v. for 4 h) was started
immediately after reopening of MCA after a 1-h occlusion. The infarct volume was mea-
sured two days later. Repinotan reduced cortical brain injury by 81, 97, and 84% at doses
of 1, 10, and 100 ìgkgh, respectively (33,97). In addition, at 1 ìgkgh the drug re-
duced injury in the caudate putamen by 67% and completely prevented reperfusion injury
in the hippocampus (33). In another study the infarct volume reduction was also measured
in the hippocampus at 7 days after i.v. infusion of repinotan (at 1, 3, or 10 ìgkgh) for
a period of 4 h immediately after 10 min of tMCA-O (123). At the lowest dose used
(1 ìgkgh) repinotan caused only a 10% reduction of neuronal damage in the CA1 area
of hippocampus; at the higher doses (3 and 10 ìgkgh) repinotan had significant effect
(123). This lack of neuroprotective efficacy at the higher doses was probably due to a
strong reduction of mean arterial blood pressure during infusion of the drug (111). DNA
fragmentation, as a measure for induced apoptosis in the hippocampus and striatum, was
examined using TUNEL-staining and gel-electrophoresis in the latter study. The neuro-
protective dose of repinotan (1 ìgkgh) was administered for 4 h immediately after
10 min tMCA-O; it strongly reduced DNA fragmentation in the hippocampus and stria-
tum, as measured by gel-electrophoresis at 4 days after tMCA-O (123). Furthermore, at 3
days after tMCA-O, the compound reduced the number of TUNEL-stained cells both in
the hippocampus (10% reduction) and in the (dorsolateral region of) striatum (123).
Traumatic brain injury (acute subdural hematoma, aSDH)
In rats with traumatic brain injury repinotan was administered either as intravenous
(triple) bolus injection immediately, at 2 or at 4 h after injury, or as a 4-h long infusion. By
the triple bolus i.v. injection repinotan produced maximal neuroprotection at doses of 10
to 100 ìgkg. There were no differences in the effects produced at the minimal as com-
pared to the maximal doses, with brain damage reduction being 60 ± 15.5 and 64 ± 15% at
10 and 100 ìgkg, respectively (33,62,97).
Repinotan was also administered intravenously at 15 min before injury and as a con-
tinuous infusion for 4 h after induction of aSDH. Pretreatment with repinotan (3 or
10 ìgkgh) produced a 40% reduction in the size of ischemic brain damage. The volu-
mes of damaged brain in the control, high-dose and low-dose groups were 106 ± 33,
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61 ± 49, and 59 ± 35 mm3 (mean ± S.D.), respectively (6). Other authors administered re-
pinotan doses ranging from 0.3 to 1000 ìgkgh by continuous infusion for 4 h, starting
immediately after induction of aSDH (post-treatment). Repinotan reduced damaged brain
volumes by 76 and 69% at 1 and 10 ìgkgh, respectively (33,62).
Repinotan has also been tested in a clinically relevant contusion model of traumatic
brain injury (TBI) (71). The drug was infused intravenously at 10 ìgkgh for 4 h, starting
at 5 min after injury. Repinotan reduced mean cortical tissue damage volume by ca. 19%
(20.18 ± 1.51 vs. 24.89 ± 1.60 mm3 in the vehicle group). The number of morphologically
intact hippocampal CA1 and CA3 neurons was also increased by repinotan. The effects of
repinotan on vestibulomotor function, spatial learning and memory deficits have been ex-
amined in this study. The drug treatment did not enhance vestibulomotor function as as-
sessed in beam balance and beam walk tasks on post-operative days 1–5, but improved
Morris water maze learning of traumatized animals (71). Motor function recovery was de-
monstrated in earlier studies as an improvement in motor behavior deficits after treatment
with repinotan. This drug enhanced and accelerated the recovery of abnormal hindlimb
grasping reflex and forelimb flexion compared with vehicle-treated controls for up to 42
days after brain injury (46).
In summary, repinotan has been shown to produce beneficial effects in a clinically rel-
evant model of TBI, as concluded from both anatomical and functional parameters. Motor
and memory impairments are common following human traumatic brain injury, and a
treatment strategy employing repinotan may accelerate functional recovery.
Dose-response curve and therapeutic time window
In various in vitro experiments repinotan did not have a clear dose–response curve. In
chick neurons there was a dose-response curve for repinotan for neuronal viability, but not
for percentage of apoptotic neurons (4). There was also no clear relationship between the
drug dose and the firing rate of dorsal root ganglion neurons probably because of the
limited range of effective drug concentrations (34). Other experiments indicated, however,
that the dose–response curve for repinotan is a wide U-shaped curve (62,75,97,129),
which has previously been observed with other compounds (96). This may indicate that
repinotan is very potent in a wide low-dose range, but produces adverse effects at higher
doses (75,97). In addition, repinotan appeared to be more potent and exhibited a broader
dose–response curve and larger dose variability after administration as a 4 h continuous
infusion, compared to (triple) bolus injection. This is probably due to the fact that in-
fusion, contrary to bolus administration, maintains brain levels of the compound in the op-
timal range throughout time of application (97).
To assess the therapeutic time-window of repinotan, the drug was administered by con-
tinuous 4-h long infusion with a delay of either 1, 3, or 5 h in the pMCA-O model and
with 3 and 5 h in the tMCA-O and aSDH models (97). In the pMCA-O model, delaying
infusion by 1 h did not reduce neuroprotective efficacy at either 3 or 10 ìgkgh (33).
After a 3 h delay, neuroprotection was still observed with 48% infarct volume reduction at
3 ìgkgh (62,97). When administration of repinotan was delayed for 5 h, a dose of
3 ìgkgh still caused a moderate 26% infarct reduction (33,62). However, when the dose
of repinotan was increased to 10 ìgkgh, the infarct volume was reduced by 43% (97).
When in the tMCA-O model the administration of repinotan HCl (10 ìgkgh) was de-
layed by 3 or 5 h, the infarct volumes were still decreased by 80% (97). When in the
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aSDH model the treatment with repinotan (3 or 10 ìgkgh) was delayed by 3 h, the drug
still produced 74% protection. When the treatment was delayed by 5 h there was still a
54% protection (33,97). There was no difference in the effects of repinotan at the two
doses used.
Thus, the therapeutic time window of repinotan appeared to be at least 5 h in in vivo
models used to assess the neuroprotective efficacy of the drug. Moreover, because of the
suggested broad dose–response curve for repinotan, the therapeutic window might be
larger than 5 h when the dose is increased in delayed administration models.
PUTATIVE MECHANISMS UNDERLYING
THE NEUROPROTECTIVE EFFECT OF REPINOTAN
Several putative mechanisms of neuroprotective action of repinotan have been ex-
amined. These mechanisms included neuronal membrane hyperpolarization, modulation
of glutamatergic neurotransmission, antiapoptotic effects, effects on intracellular signal-
ing, and modulation of the effects of neurotrophic factors.
Receptor binding of repinotan
Repinotan has a Ki of 0.19 nM (calf hippocampus), 0.25 nM (rat and human cortex),
and 0.59 nM (rat hippocampus). These Ki values reflect very high affinity receptor bind-
ing in comparison to many other CNS-active drugs. The 5-HT1A receptor affinity of repi-
notan is ca. 1.5 to 10 times (depending on the particular brain tissue) and 5 to 15 times
lower for other 5-HT1A agonists: 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT)
and ipsapirone, respectively. Functionally, in both, in vitro and in vivo electrophysiologi-
cal assays, repinotan was found to suppress neuronal firing more potently than
8-OH-DPAT and ipsapirone. The potency difference was about 1 and 2 orders of mag-
nitude, respectively (34).
Repinotan binds with lower affinity to 5-HT7 (Ki = 6 nM), á1- and á2-adrenergic
(Ki = 6 and 7 nM, respectively), 5-HT1D (36 nM), dopamine D2 and D4 (48 and 91 nM, re-
spectively), ó sites (176 nM) and 5-HT2C (310 nM) receptors. However, the binding
profile of repinotan is considered to be relatively selective, as at least one order of mag-
nitude separated its binding to 5-HT1A receptors from its binding to other receptors or
binding sites (33,35,36). In addition, the binding is considered to be stereo-selective as the
affinity of the (1)-enantiomer, BAY x 3703, was about 10-fold lower than that of repinotan
(36). Consequently, it was concluded that the pharmacological effects of repinotan are me-
diated mainly by 5-HT1A receptors.
Selective Antagonism at the 5-HT1A Receptors by WAY 100635
The conclusion that the effects of repinotan are mediated mainly by 5-HT1A receptors
has been supported by multiple studies with a selective 5-HT1A receptor antagonist
N-(2-(4-(2-methoxyphenyl)-1-piperazinyl) ethyl)-N-(2-pyridinyl) cyclohexanecarboxami-
de trihydrochloride (WAY 100635), which has no, or only very low affinity to other pu-
tative central receptors (43,69). Pretreatment with WAY 100635 potently and completely
blocked the neuroprotective effects of repinotan both in vitro and in vivo (3,4,22,34,36,37,
CNS Drug Reviews, Vol. 11, No. 4, 2005
REPINOTAN HCL 387
73,96,123,129,136). Moreover, the involvement of á-adrenoceptors and dopamine re-
ceptors was excluded since the antiapoptotic effect of repinotan (4) and its other actions at
0.1 mgkg, i.p. were not comparable with those of either á1- and á2-adrenergic antago-
nists, prazosin and idazoxan, or of D2-receptor antagonist, raclopride (36).
Chick neurons were found to be insensitive to WAY 100635 (4). It was suggested
that WAY 100635 has a lower affinity for the avian than for the rat 5-HT1A receptors.
In addition, there were subcellular and regional differences in the inhibitory potency of
WAY 100635 (25,77).
Glutamate Release
In order to evaluate whether modulation of glutamatergic neurotransmission may be in-
volved in the neuroprotective properties of repinotan, the effects of the drug on glutamate
excitotoxicity were examined in vitro and in vivo.
To study the in vitro effects of repinotan on glutamate excitotoxicity, hippocampal cells
were exposed to either 75 mM KCl (96) or to 0.5 mM L-glutamate for 1 h in serum-free
medium (129). Basal glutamate release was not affected by repinotan at concentrations up
to 5 ìM (96). However, repinotan inhibited potassium-stimulated glutamate release in a
concentration-dependent manner. Maximal inhibition was achieved at 5–10 ìM; at these
concentrations the stimulated glutamate release was nearly completely blocked (96). Hip-
pocampal cells, exposed to L-glutamate only, showed a neuronal damage of approxi-
mately 70%. If repinotan (0.0001–1 ìM) was added immediately after glutamate, it re-
duced excitotoxic damage in a concentration-dependent manner, with only about 40%
neuronal damage at 0.1 and 1 ìM. Additionally, the drug preserved the cell morphology
and the integrity of neuronal network (129).
In vivo, the effects of repinotan HCl on ischemia-induced glutamate-release were ex-
amined in the pMCA-O model using microdialysis technique (96). The drug was adminis-
tered as a bolus injection directly after pMCA-O. At 1 or 10 ìgkg repinotan reduced re-
lease of glutamate by 41.6 ± 10.5 and 54.2 ± 14.1% of control values, respectively. This
reduction reached statistical significance only for the lower dose group. This was at
variance with other studies, which did not find any difference in the neuroprotective ef-
fects of repinotan at these two doses (62,97).
In summary, the 5-HT1A receptor-mediated decrease in ischemia-induced glutamate re-
lease may explain the neuroprotective efficacy of repinotan. Repinotan could mediate the
decrease in extracellular glutamate through two basic mechanisms: (i) inhibition of glu-
tamate release from synaptic vesicles or from glial cells provoked by reversed glutamate
transport andor (ii) stimulation of glutamate uptake. However, repinotan has not yet been
found to interact directly with any of the currently known glutamate transporters, thus
making it unlikely that its activity was due to direct modulation of glutamate transport.
Inhibition of glutamate release by repinotan is more likely to be mediated by its hyperpo-
larizing action as demonstrated in vitro as well as in vivo (16,21,33,36,96,116).
Hyperpolarization and Altered 5-HT Neurotransmission
In vitro (33) and in vivo (21) experiments showed that repinotan induced a long lasting,
but reversible, inhibition of neuronal firing. Its effective in vitro concentrations were as
low as 1 nM. In vivo, biologically active doses of repinotan were 10–100 times lower
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(e.g., 0.3–100 ìgkg) than those of the classical 5-HT1A receptor agonist, 8-OH-DPAT
(6,33,37). The low systemic doses of repinotan required to inhibit cell firing and 5-HT
release are consistent with its high in vitro affinity (<10–9 molL) for native or cloned
5-HT1A receptors (36).
In vivo, repinotan-induced hyperpolarization and the subsequent reduction of 5-HT re-
lease is thought to be the result of activation of both, pre- and post-synaptic 5-HT1A re-
ceptors (17,22,37). By systemic administration repinotan (10–100 ìgkg s.c.) dose-de-
pendently diminished 5-HT output in the dorsal (DR) and median raphe nucleus (MnR)
and in two areas of the rat forebrain, the medial prefrontal cortex (mPFC) and the dorsal
hippocampus (dHPC) in a region-selective manner (21). Furthermore, the effect of repino-
tan on 5-HT output was greater than that produced by equivalent doses of other selective
5-HT1A receptor agonists, such as 8-OH-DPAT, alnespirone or ipsapirone under the same
experimental conditions (20–22). Repinotan has apparently a comparatively higher po-
tency in vivo (33,36).
At a dose of 100 ìgkg s.c., the maximal effects of repinotan were observed in the
MnR and mPFC, and moderate effects in the DR and dHPC with the decrease in release to
~15% and ~45% of the baseline level, respectively. The maximal reduction of the 5-HT
output took place at 40–60 min after drug administration. 5-HT values returned to baseline
at ca. 26 h after administration, except at the 100 ìgkg dose in mPFC. Application of
repinotan in the mPFC and DR (30 ìM) diminished the local 5-HT output to 40% and
25% of baseline, respectively (21,22). In addition, local application of the drug inhibited
neuron firing activity in the DR to ~20% of baseline, and that in mPFC to ~50% of base-
line (21). Thus, since the reduction in forebrain 5-HT output does not appear to depend
exclusively on the DR or MnR origin of the 5-HT fibers, post-synaptic together with pre-
synaptic 5-HT1A receptors in the raphe also seem to participate in the lessening of seroton-
ergic activity and 5-HT release elicited by repinotan.
The lower firing activity of 5-HT neurons in the dorsal raphe nucleus after chronic ad-
ministration of repinotan (1.25 mgkgday for 2 days) showed subsequent gradual re-
covery and returned to normal after 7 days of treatment. This recovery of firing activity
was much longer after administration of repinotan than other known 5-HT1A agonists.
This suggests that the dissociation of repinotan from the 5-HT1A receptors occurs very
slowly (37). In contrast, the postsynaptic 5-HT1A receptors (in the hippocampus) showed
unaltered responsiveness during long-term administration of repinotan (37). The desensiti-
zation of somatodendritic 5-HT1A autoreceptors results in a normalization of the firing ac-
tivity of 5-HT neurons. Moreover, an enhancement of the tonic activation of the postsy-
naptic 5-HT1A receptors takes place after a long-term treatment with 5-HT1A receptor
agonists (50). The normalized 5-HT release and the enhanced postsynaptic 5-HT1A re-
ceptor sensitivity in the target areas tend to strengthen the efficacy of 5-HT in causing
membrane hyperpolarization and neuroprotection. Thus, hyperpolarization enhances the
efficacy of 5-HT neurotransmission and appears to be one of several mechanisms of the
neuroprotective effect of repinotan.
In addition to hyperpolarization and inhibition of glutamate release (16,21,33,96,116)
voltage-independent blockade of N-, P-Q-, and T-type voltage-dependent Ca2+ channels
via G-protein-mediated signaling mechanisms (137) and direct reduction of glutamate re-
lease (121,134) have been suggested as possible mechanisms of the neuroprotective action
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of repinotan. However, no studies have been published in support of the involvement of
these mechanisms in the neuroprotective effect of repinotan.
Repinotan, Hypothermia, and Blood Flow Parameters
Hypothermia is considered to be one of the classic symptoms of 5-HT1A receptor acti-
vation (34,57,99). Furthermore, hypothermia has been shown to be neuroprotective and to
enhance functional outcome following different experimental procedures, including TBI
(28,145). Hypothermia has also been reported to improve functional outcome in severely
brain-injured patients (71,93). Repinotan reduces body temperature in a dose- and time-
dependent manner. The maximal reduction of body temperature after repinotan was 2.5°C,
it occurred at 0.5–1 h after drug administration. Hypothermia was no longer observed at
2 or 4 h after i.v., i.p., or p.o. administration (36).
The neuroprotective efficacy of repinotan does not seem to be due to its possible hypo-
thermic effect. In several studies neuroprotective activity of repinotan was found to be in-
dependent of its effect on body temperature (33,71). However, since during surgery the
body temperature of rats was kept artificially physiological, it is conceivable that after
surgery the general stressful condition might mask the hypothermic effect of repinotan. In
any case it is still possible that combining repinotan treatment with hypothermia may
produce greater beneficial effects than either treatment alone (71).
In addition, the neuroprotective efficacy of repinotan did not seem to depend on its pos-
sible effect on the regional cerebral blood flow (rCBF) in animals (33). At two hours after
start of continuous i.v. infusion of the drug, the most effective neuroprotective doses of
repinotan were 1 or 3 ìgkgh. At these or higher doses repinotan had only negligible ef-
fects on rCBF in the cerebral cortex, nucleus accumbens or thalamic nuclei. Furthermore,
repinotan did not affect arterial blood pressure, blood glucose levels, or arterial pH, pCO2,
and pO2 in different in vivo models (6,75,123,129). Thus, alterations in these parameters
did not seem to contribute to the neuroprotective potency of repinotan.
Involvement of Neurotrophic Factor S-100â
S-100 is a set of small, highly acidic, calcium-binding dimer proteins of approximately
20 kDa, which are widely distributed in different tissues. The S-100 proteins are produced
by a wide variety of normal and neoplastic cells, including brain cells (42,103). Three sub-
types of S-100 proteins, formed by dimeric combinations of the á- and the â-chain, are
known; S-100áo (áá), S-100á (áâ), and S-100â (ââ).
In the brain, S-100â is synthesized in and released by astrocytes. Its expression is di-
rectly related to the level of serotonin (52) and shown to be triggered by stimulation of
5-HT1A receptors (8,142). The release of S-100â has been suggested to be involved in the
neurotrophic effects of serotonin during early development (8,144), when serotonin stimu-
lates neurite extension and sprouting in serotonergic neurons (138,140). In the adult brain,
S-100â plays a role in neuronal plasticity (10,141) and long-term potentiation (47,80).
However, it is controversial whether S-100â is an apoptosis-inducing (42,44) or a
neuroprotective protein (13). Because different concentrations of S-100â were used in
these studies it is conceivable that S-100â may act as a cell survival factor at nanomolar
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and as an apoptosis-inducing agent at micromolar concentrations. In any case, the effect of
S-100â seems to depend on the developmental stage of the neurons and their density.
Furthermore, the role of S-100â during ischemia is still unclear. The levels of S-100â
are known to be increased in the cerebrospinal fluid of stroke patients (70) and patients
with traumatic brain injury (56). The increased S-100â immunoreactivity in the brain was
related to the extent of neuronal damage. Therefore, the S-100â level is considered a
marker for the activation of astrocytes and the S-100â levels in the blood are used as an in-
dicator of the infarct volume and of prognosis in acute stroke (100,119). However, it is
still unclear whether the increase in S-100â immunoreactivity reflects the astroglial re-
sponse to injury, whether it causes or enhances neuronal damage or whether it is cellular
defense mechanism against oxidative stress.
The role of S-100â during ischemia was examined (3) to elucidate whether S-100â can
protect neurons against glutamate- or staurosporine-induced damage and whether S-100â
is involved in the protective effect of repinotan against staurosporine-induced apoptosis
(136). S-100â (1–10 ngmL) protected rat hippocampal neurons from both glutamate-in-
duced excitotoxicity and staurosporine-induced apoptosis. In addition, S-100â protected
chick embryonic neurons from staurosporine-induced apoptosis.
Repinotan increased S-100â levels both in vitro and in vivo. When repinotan was in-
fused at 4 ìgkg i.v. over 4 h to rats, the S-100â levels were elevated at 6 h after termi-
nation of the infusion, in striatum but not in the hippocampus (3). This latter finding was
in accordance with earlier studies (11). In cultured rat cortical astrocytes, a twofold in-
crease in the release of S-100â was reported after incubation for 6 and 24 h with repinotan,
1 nM (3). Finally, S-100â antibody partially inhibited the anti-apoptotic effect of repinotan
against staurosporine-induced apoptosis (3). Thus, S-100â was shown to contribute, at
least partly, to the anti-apoptotic effects of repinotan. This result is in accordance with the
finding that there is a correlation between increased S-100â availability in the extracellu-
lar space and a marked improvement in dendrite recovery after ischemia (117) adding
further evidence for a S-100â role as a mediator of 5-HT1A-induced neuroprotection.
Involvement of Nerve Growth Factor (NGF)
The partial 5-HT1A agonist 8-OH-DPAT has been shown to protect chick embryonic
neurons against apoptosis induced by serum deprivation. More importantly, the expression
of nerve growth factor (NGF) was suggested to be partially involved in its mechanism of
action (5).
To examine whether NGF is also involved in the neuroprotective effects of repinotan,
the neuronal NGF secretion of chick neurons incubated in medium with or without serum
was measured in the presence or absence of the drug (4). Under control conditions (medi-
um with serum), repinotan increased secretion of NGF into the culture medium. Similarly,
in vivo, NGF content of rat hippocampus was increased at 6 h after a 4 h-long intravenous
infusion of repinotan,4 ìgkg. The NGF levels returned to baseline levels at 12 h after ter-
mination of repinotan infusion. The drug had no effect on NGF content of the striatum.
Under conditions of serum withdrawal, the NGF content of the culture medium was in-
creased and not further elevated by repinotan. However, NGF antibodies (10 ngmL) in-
hibited the neuroprotective effect of repinotan, 1 ìM, in chick neurons suggesting that
the drug affected NGF signaling pathway leading to a synergistic effect of NGF and repi-
notan (4).
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Signaling Pathways after 5-HT1A Receptor Stimulation by Repinotan.
MAPK-Pathways: Induction of NGF and BCL-2,
and Inhibition of Caspase-3
The stimulation of the 5-HT1A receptor can lead to the activation of the mitogen-acti-
vated protein kinase (MAPK) cascade (49), and thus influence gene expression. Specifi-
cally, the isoforms of extracellular signal-regulated protein kinase (ERK)12 of the
MAPK family have been linked to the inhibition of apoptosis (143). In the hippocampal
neuron-derived cell line HN-2-5 a peak activation of ERK12 occurred after 30 min of
treatment with repinotan, 100 nM (2). Subsequently, after terminating the drug treatment,
the activation decreased dramatically to virtually basal levels in 3 h, which is different
from the prolonged activation of ERK observed in 8-OH-DPAT-treated HN-2-5 cells (1)
and could be attributed to the lower chemical stability of repinotan in aqueous solution
(2). Dose-response analysis revealed that repinotan-triggered ERK12 activation was
quite significant even at nanomolar concentrations of the drug. Similar to the dose-re-
sponse curve of 8-OH-DPAT, the ERK12 stimulation reached a maximum at 100 nM of
repinotan and then remained unchanged up to at least 1 ìM.
In fibroblasts, ERK can be activated through the transfected human 5-HT1A receptor
(45). In these cells 5-HT1A receptor stimulation eventually leads to activation of ERK
(104). In the hippocampal neuron-derived cell line HN-2-5, increased phospholipase C
(PLC) activity seemed to be essential for the activation of ERK12. This was supported by
elimination of the 5-HT1A receptor-mediated activation of ERK12 by the PLCâ inhibitor
U73122 (29). In addition, the general protein kinase C (PKC) inhibitor GFX did not block
signaling upstream of ERK12 (2), confirming that 5-HT1A receptor-mediated-activation
of ERK12 also in this cell line probably occurs through a Ras  Raf  MEK 
ERK12 cascade and not through a PKC  Raf pathway. Interestingly, the MAPK
pathway is shared by both, NGF and Bcl-2 signaling.
The exact molecular pathway of the effect of repinotan on NGF is still unclear. Other
drugs have been shown to induce NGF protein and NGF mRNA by increasing the intracel-
lular cAMP concentrations (101,125,128). As mentioned above, repinotan increased NGF
secretion in in vivo (rat) as well as in vitro (chick neurons). In chick neurons, stimulation
of 5-HT1A receptors is also coupled to an activation of adenylate cyclase and to an in-
crease in the intracellular c-AMP content (41). In addition, as mentioned earlier, repinotan
causes hyperpolarization which induces elevated intracellular potassium concentration,
which in turn increases the concentration of NGF-mRNA in cultured hippocampal
neurons (89,147).
Similarly, the exact molecular pathway of the effect of repinotan on proteins of the pro-
to-oncogene B-cell lymphoma protein 2 (Bcl-2) family is only partly unraveled (75). The
Bcl-2 and its related proteins are known to be major players in cell survival after brain
injury. The Bcl-2 family contains both inhibitors (e.g., Bcl-2, Bcl-XL) and promoters
(e.g., Bcl-2-associated protein X (Bax), Bcl-2-associated death promoter homologue) of
cell death, and the ratio between these two types of proteins contributes to the vulnera-
bility of an individual cell towards damaging stimuli (60). Interfering with Bcl-2 family
protein expression by systemically administered drugs was proposed to be an interesting
pharmacological approach to stroke therapy, especially during the first 24 h after damage
(26,48,64).
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Repinotan (1 or 3 ìgkgh) was infused intravenously immediately after a 45-min
ischemic period due to tMCA-O. At 6, 12, 24 h after the start of reperfusion Bcl-2 and Bax
protein levels in the cerebral cortex were calculated (75). The treatment resulted in ele-
vated Bcl-2 protein level in the ipsilateral cerebral cortex as early as 6 and 12 h after the
start of reperfusion. This effect became more pronounced at 24 h. Repinotan had no effect
on Bax content during reperfusion. In both cases, there was no difference between the ef-
fects of the drug at the two doses.
Thus, repinotan was found to increase Bcl-2 protein levels, which were shown to be
neuroprotective during ischemia andor reperfusion (33,97,123). The increase in BCL-2
protein content could contribute to the neuroprotection at 6 and 12 h of reperfusion (75).
Bcl-2 promoter activation has recently been shown to be regulated via MAPK (ERK)
p42p44 in vitro (85). Thus, it was hypothesized that stimulation of 5-HT1A receptors with
repinotan contributes to the activation of the MAPKERK signalling pathway followed by
induction of Bcl-2 protein (75), which in turn promotes cellular survival. Although repino-
tan did not seem to have an effect on Bax content during reperfusion, Bax regulation,
similar to Bcl-2, has also been linked to the ERK12 cascade in several cell lines (59).
However, the knowledge of molecular pathways of Bax protein regulation is still very
limited and it is unknown whether Bcl-2 and Bax proteins are regulated via the same, or
different, molecular pathways in the brain in vivo, and how this regulation is changed
under pathological conditions such as ischemiareperfusion (75).
Furthermore, through a MAPK cascade, stimulation of the 5-HT1A receptor with repi-
notan leads to a phosphoinositide-3-kinase (PI-3K)-independent inhibition of the pro-apo-
ptotic, cysteinyl aspartate-specific protease, caspase-3 (2), which actually causes the cyto-
skeletal breakdown that defines apoptosis (1,49). Since many conditions of neural insult
and degeneration culminate in the activation of caspase-3, it is clearly the common down-
stream protease that has to be somehow inhibited to cause suppression of apoptosis. The
5-HT1A receptor-mediated inhibition of caspase-3 could be used as a general tool to
prevent neuronal apoptosis.
Downstream of ERK12, the enzyme PKCá has been found to provide a link between
the 5-HT1A receptor and the pro-apoptotic enzyme caspase-3 in the hippocampal neuron-
derived cell line HN-2-5 (2). Earlier studies already showed that drugs which activate
PKC promote cell survival (88), and inhibitors of PKC, such as staurosporine (136),
induce apoptosis.
Since phosphorylation is important for proper activation and turnover of the PKCá mol-
ecule (51) and one of the different phosphorylation sites of PKCá, the Thr638 residue, is
within a MAPK recognition sequence (2), ERK12 was thought to regulate PKCá through
direct phosphorylation. Likewise, caspase-3 was suggested to be inhibited through phos-
phorylation by PKCá.
CLINICAL TRIALS
Preclinical studies with repinotan suggested that the drug should be effective in the pre-
vention of secondary brain damage in brain-injured patients suffering from acute ischemic
stroke or traumatic brain injury. The safety and tolerability of repinotan at three different
doses (0.5, 1.25, or 2.50 mgday) were assessed in patients with severe traumatic brain
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injury (107). On a descriptive basis, the proportion of patients having good outcome or
moderate disability based on Glasgow Outcome Scale was somewhat higher in repinotan-
treated (60%) than in placebo-treated patients. Further clinical studies were designed to
demonstrate the benefit of repinotan treatment in traumatic brain injury and preliminary
results appeared to be favorable.
In the completed Phase IIb clinical trial (from 2002 to 2004) in patients with acute
ischemic stroke repinotan did not meet the expectations raised by the preclinical studies.
This randomized, double blind, placebo-controlled trial has been completed but not yet
published. According to the press release from Bayer AG the results were negative
(BAYNEWS International, December 23, 2004).
CONCLUSIONS
Repinotan, a drug with a good safety profile (33,92,107), was found to have pro-
nounced neuroprotective effects in various ischemia models (pMCA-O, tMCA-O, and
aSDH) that mimic different aspects of brain injury. Under pMCA-O conditions, repinotan
HCl caused a strong, dose-dependent infarct reduction, with maximal reduction of infarct
volume found in the 1–10 ìgkg dose range (62,97,129). In the tMCA-O model, applica-
tion of repinotan HCl also resulted in a pronounced reduction in infarct volumes (33,97,
123). In an SDH model repinotan was also clearly neuroprotective (6,61,71,97).
In patients with acute ischemic stroke, however, the primary endpoint of the clinical
trial was not met and the anticipated clinical benefits of repinotan could not be demon-
strated. Preliminary observations in human patients suggested a probable beneficial action
of repinotan in traumatic brain injury (107). A detailed comparison of neuroprotective ef-
fects, plasma levels, side effects, pharmacokinetic and pharmacodynamic effects of repi-
notan in human patients and experimental animals is in preparation.
In the experimental models the neuroprotective effects of repinotan were mediated by
5-HT1A receptors, since the specific 5-HT1A receptor antagonist WAY 100635 blocked all
effects of repinotan in vivo (21,22,34,36,39,73,96,123). Pretreatment with repinotan was
not required to achieve neuroprotection. The drug reduced neuronal degeneration when it
was added immediately after induction of injury. Post-treatment seemed to be more ef-
fective than pretreatment in the aSDH paradigm (6,33,61,62).
The proposed neuroprotective mechanisms of repinotan are thought to involve neuro-
nal hyperpolarization via activation of G protein-coupled inwardly rectifying K+ channels
(33,68). This hyperpolarization is induced through activation of both pre- and post-
synaptic 5-HT1A receptors (17,22,37) and reduced glutamate release (16,21,33,36,96,116).
In vitro repinotan decreased neuronal damage caused by glutamate in primary hippocam-
pal cultures (96,129) and preserved cell morphology and integrity of the neuronal network
(129).
In addition, voltage-independent blockade of N-, P-Q-, and T, and L-type voltage-de-
pendent Ca2+ channels via G-protein-mediated signaling mechanisms (19,98,137), and
direct reduction of glutamate release (121,134) have been suggested as other probable
mechanisms by which repinotan may exert its neuroprotective effects. These mechanisms
could explain the neuroprotective efficacy of repinotan per se, but not necessarily its ef-
ficacy by delayed administration. The therapeutic time window of repinotan appeared to
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be at least 5 h in in vivo models used to assess its neuroprotective efficacy (33,62,97). Its
therapeutic window at higher doses may be even longer than 5 h (97).
It is likely that other processes involved in the pathogenesis of brain injury could be af-
fected by repinotan. The neuroprotective efficacy of repinotan cannot be attributed to in-
duction of hypothermia (33,75,96) or to involve an effect on local cerebral blood flow
(33), arterial blood pressure, blood glucose levels, or changes in the arterial pH, pCO2, or
pO2 (6,75,123,129). The neuroprotective efficacy of repinotan could be related to its
antiapoptotic effect that may be distinct from its hyperpolarizing effect or modulation of
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Fig. 2. Simplified diagram of the neurotoxic cascade of neurodegenerative processes after onset of an ischemic
stroke. Major events are the loss of ionic balance and prolonged depolarization, overexcitation by glutamate,
intracellular calcium accumulation and initiation of apoptotic cell death pathways. Apart from the neurotoxic
cascade neuroinflammatory processes are triggered that activate neurodegenerative or neuroprotective intracellu-
lar signaling pathways. The efficacy of the neuroprotective potential of repinotan is based on the hyperpolarizing
effect of binding to the 5-HT1A receptor and the subsequent reduction of membrane depolarization. Not indicated
in the Figure are the effects of repinotan on nerve growth factor, S-100â and intracellular molecular signaling
processes which are either directly or indirectly influenced by the drug. Adapted with permission from ref. 30.
glutamate release. In vitro, in mixed neuronalglial cultures repinotan protected cells from
serum deprivation-induced (4), as well as from staurosporine-induced apoptosis (3,136).
In vivo repinotan protected hippocampal and striatal neurons from apoptosis after
tMCA-O (123). All these effects were blocked by the specific 5-HT1A receptor antagonist
WAY 100635, showing a specific 5-HT1A receptor-mediated effect.
Furthermore, repinotan increased the levels of death-inhibiting protein Bcl-2 in rat
brains during ischemiareperfusion (75) and levels of S-100â, a serotonergic glial growth
factor that has been reported to protect cultured neurons against glutamate-induced
damage (3). Both of these mechanisms may contribute to the neuroprotective efficacy of
repinotan. In addition, repinotan was found to affect the NGF signaling pathway sug-
gesting a synergistic effect with NGF (4). Finally, repinotan has been shown to suppress
caspase-3 through MAPK and PKCá (2). This seems to be another pathway through which
repinotan could exert its neuroprotective effect.
The ultimate goal of neuroprotective therapy is to restrict the severity of initial damage
and to improve neurological outcome and, therefore, the quality of life. In the clinically
relevant model of TBI repinotan did not seem to enhance vestibulomotor function as as-
sessed in beam balance and beam walk tasks (71). Earlier studies showed an improved and
accelerated recovery of abnormal hindlimb grasping reflex and forelimb flexion as com-
pared with vehicle-treated controls for up to 42 days after brain injury (46). Repinotan
also attenuated neocortical lesion-induced spatial learning and memory deficits in a
Morris water maze (71). Supportive correlative behavioral, neuroanatomical and neuro-
chemical evidence show that repinotan attenuates NMDA-induced delayed neuronal death
in rat MBN when administred at 2 or 3 days after injury (54,55). Thus, treatment with re-
pinotan seems to be beneficial in a clinical context, since impairments in memory and
learning and motor regulation are common following ischemic human brain injury.
In conclusion, the dose- and time-dependent neuroprotective efficacy of repinotan in
preclinical studies indicate that this drug is a promising candidate for prevention of sec-
ondary brain damage in brain-injured patients suffering from acute ischemic stroke or
traumatic brain injury. The anticipated clinical benefits could not be, however, de-
monstrated in acute ischemic stroke patients in the first comprehensive clinical trial. It is
still possible that repinotan could be effective in the treatment of traumatic brain injury in
humans.
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